Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis.
Martin OrbanJan KleebergerTaoufik OuarrakAnne FreundHans-Josef FeistritzerGeorg FuernauTobias GeislerKurt HuberDariusz DudekMarko NocGilles MontalescotAlexander NeumerPaul HallerPeter ClemmensenUwe ZeymerSteffen DeschSteffen MassbergSteffen SchneiderHolger ThieleJörg HausleiterPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2021)
This pooled sub-analysis is the largest analysis on safety and efficacy of three oral ADP-receptor antagonists and shows that acute therapy with either clopidogrel, prasugrel or ticagrelor is no independent predictor of 1-year mortality. Treatment with ticagrelor seems independently associated with less in-hospital moderate and severe bleeding events compared to clopidogrel. This finding might be due to selection bias and should be interpreted with caution.
Keyphrases
- percutaneous coronary intervention
- acute coronary syndrome
- acute myocardial infarction
- antiplatelet therapy
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- coronary artery disease
- healthcare
- clinical trial
- atrial fibrillation
- stem cells
- randomized controlled trial
- cardiovascular events
- mesenchymal stem cells
- cardiovascular disease
- type diabetes
- risk factors
- left ventricular
- drug induced
- open label
- acute care
- phase ii